MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcard.2024.132375

Медицинская библиотека · International journal of cardiology · 2024

Clinical effects of direct oral anticoagulants in elderly patients with a bioprosthetic valve and atrial fibrillation.

Amano Masashi, Takegami Misa, Miyake Makoto, Kitai Takeshi, Fujita Tomoyuki, Koyama Tadaaki, Tanaka Hidekazu, Ando Kenji, Komiya Tatsuhiko, Izumo Masaki, Kawai Hiroya, Eishi Kiyoyuki, Yoshida Kiyoshi, Kimura Takeshi, Nawada Ryuzo, Sakamoto Tomohiro, Shibata Yoshisato, Fukui Toshihiro, Minatoya Kenji, Tsujita Kenichi, Sakata Yasushi, Sugio Kumiko, Nishimura Kunihiro, Furukawa Yutaka, Izumi Chisato, BPV-AF Registry Group

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Current guidelines recommend direct oral anticoagulants (DOACs) and warfarin for patients with atrial fibrillation (AF) who have a bioprosthetic valve (BPV). However, the data related to elderly patients (aged ≥80 years) with BPV replacement and AF are limited.

METHODS

This post-hoc subgroup analysis of a BPV-AF Registry enrolled 752 patients with BPV replacement and AF. The primary net outcome was a composite of cardiac death, stroke, systemic embolism, major bleeding, and cardiovascular events.

RESULTS

Among 752 patients, 429 (57%) patients were ≥ 80 and 323 (43%) were < 80 years old. The higher risk in patients aged ≥80 than <80 years was significant for the net outcome (hazard ratio [HR], 2.04; 95% confidence interval [CI], 1.31-3.17; P = 0.001). After adjustment for confounders, there was no statistically significant difference between warfarin (reference) and DOAC users in the risk of net outcomes (adjusted HR, 1.26; 95% CI, 0.71-2.24; P = 0.44), stroke and systemic embolism (adjusted HR, 2.01; 95% CI, 0.48-8.38; P = 0.34), and major bleeding (adjusted HR, 0.73; 95% CI, 0.11-4.98; P = 0.75) in patients aged ≥80 years old as well as those aged <80 years. Among 489 warfarin users, the cumulative incidence of net outcomes tended to be higher in patients aged ≥80 than <80 years (12.2% vs. 5.7% at 1 year, log-rank P = 0.002). Among 263 DOAC users, however, it was similar between patients aged ≥80 and < 80 years.

CONCLUSIONS

The present study demonstrated that DOAC showed similar efficacy and safety compared with warfarin even in elderly patients aged ≥80 years with BPV replacement and AF.

Для цитирования: Amano Masashi, Takegami Misa, Miyake Makoto, Kitai Takeshi, Fujita Tomoyuki, Koyama Tadaaki, Tanaka Hidekazu, Ando Kenji, Komiya Tatsuhiko, Izumo Masaki, Kawai Hiroya, Eishi Kiyoyuki, Yoshida Kiyoshi, Kimura Takeshi, Nawada Ryuzo, Sakamoto Tomohiro, Shibata Yoshisato, Fukui Toshihiro, Minatoya Kenji, Tsujita Kenichi, Sakata Yasushi, Sugio Kumiko, Nishimura Kunihiro, Furukawa Yutaka, Izumi Chisato, BPV-AF Registry Group. Clinical effects of direct oral anticoagulants in elderly patients with a bioprosthetic valve and atrial fibrillation.. International journal of cardiology. 2024. DOI: 10.1016/j.ijcard.2024.132375.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.